SHARE NOW
MaxCyte and Vittoria have recently signed a strategic platform license agreement for MaxCyte’s Flow Electroporation® technology and ExPERT™ platform. Vittoria is now able to use these technologies for clinical and commercial purposes on a non-exclusive basis. MaxCyte will receive platform licensing fees and program-related revenue as part of the agreement.
The leading cell-engineering-focused company, MaxCyte, Inc., and leading-edge gene-edited cell therapeutics company, Vittoria Biotherapeutics, Vittoria, will be advancing next-generation cellular therapies. MaxCyte’s Flow Electroporation® technology and ExPERT™ platform will support Vittoria’s Senza5™ technology, designed to address current gaps with current cell therapies.
Vittoria is set to submit an IND for their lead program, Viper 101, this year. To address unmet needs in treating T-cell lymphoma, MaxCyte’s Flow Electroporation® technology and ExPERT™ platform will provide valuable support. Viper 101 is a gene-edited, autologous, dual-population cell therapy that uses Vittoria’s proprietary Senza5™ technology to enhance CAR-T treatments’ viability, efficacy, and safety. It achieves this by modulating a novel checkpoint pathway in engineered T-cells.
Nicholas Siciliano, Ph.D., CEO of Vittoria stated:
“MaxCyte’s experience with clinical grade manufacturing of gene-edited cellular therapeutics will greatly enhance the robustness and reproducibility of our manufacturing process, ensuring that each batch of our CAR-T cells meets the highest standards of consistency and quality.”
Vittoria’s Senza5™ CAR-T cells have demonstrated superior anti-tumor efficacy in liquid and solid tumor preclinical models and employ a proprietary five-day manufacturing process.
MaxCyte’s ExPERT™ instrument portfolio is the next generation of leading, clinically validated electroporation technology for complex and scalable cell engineering, delivering high-end performance through transfection efficiency, seamless scalability and enhanced functionality.
The ExPERT family of products includes four instruments: ATx™, STx™, GTx™ and VLx ™.
How are you enjoying this news article? Let us know your thoughts, here >>
“Through our partnership with Vittoria, MaxCyte has gained an opportunity to further validate and showcase our technology in a real-world setting and expand its footprint in the promising field of CAR-T therapies. We look forward to supporting Vittoria’s efforts to improve efficacy and enhance safety of T-cell therapies.” said Doug Doerfler, President and CEO of MaxCyte.
Source: MaxCyte Press Release
While we have you…
We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.
